Phaseline

Companies › ABX advanced biochemical compounds

ABX advanced biochemical compounds: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Mar 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
[18F]PSMA-1007
PSMA-targeted PET imaging agent (fluorine-18 labeled small molecule)
FOLH1Phase 3Prostate CancerMar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06122584[18F]PSMA-1007Phase 3Prostate CancerOncologyMar 2027

Targets

FOLH1 (1)

Companies with the same targets

Novartis Johnson & Johnson (Janssen) Telix Pharmaceuticals (Innovations) Clarity Pharmaceuticals Convergent Therapeutics Fusion Pharmaceuticals Five Eleven Pharma T.O.A.D. Oncology VitsGen Therapeutics Endocyte

Companies built like this

Curium US Fusion Pharmaceuticals Clarity Pharmaceuticals LaNova Medicines Zhejiang Quetzal Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.